Home > Journals > Minerva Cardiology and Angiology > Past Issues > Articles online first > Minerva Cardiology and Angiology 2021 Oct 29



To subscribe PROMO
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Minerva Cardiology and Angiology 2021 Oct 29

DOI: 10.23736/S2724-5683.21.05802-6


language: English

Assessment of sacubitril/valsartan effects on left ventricular dynamics using 3D echocardiography and 3D strain in heart failure with reduced ejection fraction patients

Tuğba K. ÖZ 1, 2 , Mahmoud ABDELNABI 3, 4, Corrado FIORE 5, Abdallah ALMAGHRABY 6, Deniz CIHAN 7, Nigar BABAZADE 8, Syed HASEEB RAZA NAQVI 9, Bahadır OMAR 10, Bahadır DAĞDEVIREN 7

1 Cardiology Department, Faculty of Medicine, Istinye University, Istanbul, Turkey; 2 Cardiology Department, Liv Hospital Ulus, Istanbul, Turkey; 3 Clinical and Experimental Internal Medicine Department, Medical research Institute, Alexandria University, Alexandria, Egypt; 4 Internal Medicine Department, Texas Tech Health Science Center, Lubbock, TX, USA; 5 Cardiology Department, Citta di Lecce Hospital GVM Care and Research, Lecce, Italy; 6 Cardiology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt; 7 Cardiology Department, Faculty of Medicine, Bahcesehir University, Istanbul, Turkey; 8 Cardiology Department, Baku Health Clinic, Baku, Azerbaijan; 9 Cardiology Department, National Institute of Cardiovascular Diseases, Sindh, Pakistan; 10 Cardiology Department, Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Turkey


BACKGROUND: Three-dimensional (3D) echocardiography and 3D strain parameters have been used for a comprehensive quantitative assessment of left ventricular (LV) myocardial dynamics. So far, there are no data on sacubitril/valsartan effects on cardiac functions and LV reverse remodeling using 3D echocardiography. This study aimed to evaluate the effects of sacubitril/valsartan on the LV functions using two-dimensional (2D) echocardiography, 3D echocardiography, and the 3D strain parameters.
METHODS: A single-center prospective cohort study which included 100 heart failure with reduced ejection fraction (HFrEF) patients with guidelines-approved indications for sacubitril/valsartan treatment. Patients received a short course (3-month) of sacubitril/valsartan. 3-month follow-up 2D, 3D echocardiographic parameters, and 3D strain were compared to baseline parameters.
RESULTS: The results of the study revealed a significant improvement in left ventricular dynamic functions at 3-month follow-up with an improvement in left ventricular systolic function (mean left ventricular ejection fraction (LVEF) increased from 27.65 ± 4.98% to 32.89 ± 6.03%, P<0.001). Comparison of HFrEF patients with ischemic and non-ischemic etiologies showed that echocardiographic parameters significantly improved in both groups after 3 months of sacubitril/valsartan treatment. There was no statistically significant difference between both groups regarding echocardiographic parameters at baseline and 3-month follow-up.
CONCLUSIONS: In a single-center prospective observational cohort study evaluating the effects of short-term (3-month course) sacubitril/valsartan treatment on LV dynamics assessed by 3D echocardiography and 3D strain, sacubitril/valsartan was associated with a significant improvement of LV systolic functions and reverse remodeling effects in both ischemic and non-ischemic HFrEF patients.

KEY WORDS: Heart failure with reduced ejection fraction (HFrEF); Sacubitril/valsartan; 3D echocardiography; 3D stain; Ventricular remodeling

top of page